Spanish competition authority CNMC has started sanction procedures against the Ireland-based Aspen Group pharmaceutical, as well as its Spanish distributor, Deco Pharma SL, over alleged abuses of market power, including denial of supply of certain drugs, excessive prices, and agreements to limit distribution and cause deliberate shortages.
The actions mentioned would be in violation of the country’s Competition Defense Law, as well as the Treaty on the Function of the European Union, by causing deliberate shortages of certain products in the national market in order to avoid the price guidelines set by the Spanish market, importing said products from other countries and allowing Aspen to set its own prices.
The CNMC’s probe was kick-started after information on these possible uncompetitive practices were notified by the Italian Competition Authority, from where some of the medications involved have been imported.
Full Content: CNMC
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
European Music Streaming Firms Rally Against Apple’s Proposed Remedies
May 9, 2024 by
CPI
Google and South Carolina Clash Over State Records Demand
May 8, 2024 by
CPI
Telefonica Germany Teams Up with Amazon Web Services to Migrate 5G Customers
May 8, 2024 by
CPI
Federal Judge Grants $7.4 Million Settlement in Pork Price-Fixing Case
May 8, 2024 by
CPI
Wilson Sonsini Bolsters Antitrust and Competition Practice with Key Partner Returns
May 8, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Ecosystems
May 9, 2024 by
CPI
Mapping Antitrust onto Digital Ecosystems
May 9, 2024 by
CPI
Ecosystems and Competition Law: A Law and Political Economy Approach
May 9, 2024 by
CPI
Ecosystem Theories of Harm: What is Beyond the Buzzword?
May 9, 2024 by
CPI
Open Ecosystems: Benefits, Challenges, and Implications for Antitrust
May 9, 2024 by
CPI